Close Get Latest Internet Explorer Get Latest Firefox Get Latest Chrome

Cancer Clinical Trials for Adults

Last updated August 2014


These cancer-related research projects are conducted by attending physicians on staff at Inova Comprehensive Cancer and Research Institute and Inova Women's Services

The following list of research trials is meant to be a general information resource only. It should not replace information given by your physician. These studies may close without warning.


Contact information

For questions regarding the status of an individual study, please contact the person or phone number listed with each individual study.


Additional resources

  • Inova Research Center provides an overview of clinical trials, why they are important and how they work. Read now.
  • In addition to the consent forms for these studies, additional information on cancer and clinical trials can be found at www.cancer.gov
  • The U.S. government has a clinical trial website with helpful information for patients. It allows people to look for trials in specific therapeutic areas: www.clinicaltrials.gov
  • The National Cancer Institute also has trial search engines and information on clinical trials

Translational Research

Protocol/Organization Study Title/Purpose Status
Inova/George Mason University
Translational Medicine Institute
Cancer Molecular Profiling Project
Purpose: To study the phosphoproteomic profile of brain, ovarian, colorectal, liver, lung and hematogenous malignancies to classify disease and develop treatments using microarray technology
Principal Investigator: Kirsten Edmiston, MD
Contact Person: Holly Gallimore, 703-776-2688
Open


Acute Myeloid Leukemia

Protocol/Organization Study Title/Purpose Status
Astellas 2215-CL-0101
A Phase 1/2 Open-Label, Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP2215 in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Principal Investigator: Alex Spira, MD, PhD, FACP
For more information on this clinical trial, call 703-208-3192
Open
USO 12-154
A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability and Pharmacodynamics of GS-9973 in Subjects with Relapsed or Refractory Hematologic Malignancies (GS-US-339-0102)
Principal Investigator: Dipti Patel-Donnelly, MD
For more information on this clinical trial, call 703-208-3192
Open


Bladder

Protocol/Organization Study Title/Purpose Status
USO 13-227
A Phase II, Multicenter, Single-Arm Study of MPDL3280A in Patients with Locally Advanced or Metastatic Urothelial Bladder Cancer
Principal Investigator: Alexander Spira, MD, PhD, FACP
For more information on this clinical trial, call 703-208-3192
Open


Breast

Protocol/Organization Study Title/Purpose Status
Inova/George Mason University
Preventing Invasive Breast Neoplasia with Chloroquine (PINC) Trial
Purpose: To study the use of chloroquine in the treatment of ductal carcinoma in situ (DCIS) and in prevention of invasive breast cancer in patients diagnosed with DCIS
Principal Investigator: Kirsten Edmiston, MD
Contact Person: Holly Gallimore, 703-776-2688
Open
ISPY-2
ISPY-2 Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis
Purpose: To study multiple novel agents in locally advanced breast cancer patients receiving neoadjuvant chemotherapy
Principal Investigator: Kirsten Edmiston, MD
Contact Person: Holly Gallimore, 703-776-2688; Maria Agra, RN, 703-720-5210
Open
Alliance A011106
Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III Study
Principal Investigator:Mary Wilkinson, MD
Contact Person: Maria Agra, RN, 703-720-5210
Open
RTOG 1005 A Phase III Trial of Accelerated Whole Breast Irradiation with Hypofractionation Plus Concurrent Boost versus Standard Whole Breast Irradiation Plus Sequential Boost For Early-Stage Breast Cancer

This study is open to enrollment at the following sites:

Inova Fairfax Hospital
Principal Investigator: Samir Kanani, MD
Contact Person: Christina Krawiecki, CCRC, 703-776-4021

Inova Alexandria Hospital
Principal Investigator: Jane Grayson, MD
Contact Person: Chloe Hamilton, RN, 703-504-7916 and 703-504-7900
Open
SWOG S1207
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer
Principal Investigator: Mary Wilkinson, MD
Contact Person: Maria Agra, RN, 703-720-5210
Open
Alliance A221101
Randomized Double-Blind Placebo Controlled Study of Subcutaneous Testosterone in the Adjuvant Treatment of Postmenopausal Women with Aromatase Inhibitor Induced Arthralgias
Principal Investigator: Mary Wilkinson, MD
Contact Person: Maria Agra, RN, 703-720-5210
Open
SWOG 1202
A Randomized Placebo-Controlled Phase III Study of Duloxetine for Treatment of Aromatase Inhibitor Associated Musculoskeletal Symptoms in Women with Early Stage Breast Cancer
Principal Investigator: Mary Wilkinson, MD
Contact Person: Maria Agra, RN, 703-720-5210
Open
Pfizer A5481023
A Multicenter Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Fulvestrant (Faslodex®) with or without PD-03232991 (Palbociclib) +/- Goserelin in Women with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer Whose Disease Progressed after Prior Endocrine Therapy
Principal Investigator: Mary Wilkinson, MD
Contact Person: Maria Agra, RN, 703-720-5210
Open
Side-Out Foundation SO-BCA-0002 Side-Out 2 A Pilot Study Utilizing Proteomic and Genomic Profiling by Reverse Phase Protein Microarray (RPMA), IHC Analysis, RNA-Seq, and Exome Sequencing of Patients' Tumors to Find Potential Targets and Select Treatments for Patients with Metastatic Breast Cancer
Principal Investigator: Nicholas Robert, MD
For more information on this clinical trial, call 703-208-3192
Open
Novartis
CBKM120F2202
A Randomized, Double-Blind, Placebo Controlled, Phase II Study of BKM120 Plus Paclitaxel in Patients with HER2 Negative Inoperable Locally Advanced or Metastatic Breast Cancer, with or without PI3K Pathway Activation
Principal Investigator: Mary Wilkinson, MD
Contact Person: Maria Agra, RN 703-720-5210
 Open
NSABP B-43
A Phase III Clinical Trial Comparing Trastuzumad Given Concurrently with Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy
Principal Investigator: Mary Wilkinson, MD
Contact Person: Maria Agra, RN 703-720-5210
 Open
USO 11-027 BELLE 4
A Randomized, Double-Blind, Placebo Controlled Phase II/III Study of BKM120 Plus Paclitaxel in Patients with HER2 Negative Inoperable Locally Advanced or Metastatic Breast Cancer, with or without PI3K Pathway Activation
Principal Investigator: Neelima Denduluri, MD
For more information on this clinical trial, call 703-208-3192
 Open
USO 13-204
Phase 1 Study of Mifepristone in Combination with Eribulin in Patients with Locally Advanced/Metastatic Breast Cancer with a Dose Expansion Cohort in Patients with Triple Negative Breast Cancer
Principal Investigator: Alex Spira, MD, PhD, FACP
For more information on this clinical trial, call 703-208-3192
 Open
USOR 13-053
A Phase Ib/II Clinical Study of BBI608 Administered with Paclitaxel in Adult Patients with Advanced Malignancies
Principal Investigator: Alex Spira, MD, PhD, FACP
For more information on this clinical trial, call 703-208-3192
 Open
Galena/Genentech ML 25749
Combination Immunotherapy with Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-Expressing Breast Cancer Patients to Prevent Recurrence
Principal Investigator: Nicholas J. Robert, MD
For more information on this clinical trial, call 703-208-3192
 Open
USOR 13-111
A Phase 3, Open-Label, Randomized, Parallel, 2-Arm, Multi-Center Study of BMN 673 versus Physician's Choice in Germline BRCA Mutation Subjects with Locally Advanced and/or Metastatic Breast Cancer, Who Have Received No More than 2 Prior Chemotherapy Regimens for Metastatic Disease
Principal Investigator: Nicholas J. Robert, MD
For more information on this clinical trial, call 703-208-3192
 Open
USO 13-128
A Multicentered, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Fulvestrant (Faslodex®) with or without PD-0332991 Palbociclib +/- Goserelin in Women with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer Whose Disease Progressed after Prior Endocrine Therapy
Principal Investigator: Nicholas J. Robert, MD
For more information on this clinical trial, call 703-208-3192
 Open
USO 13-146
A Randomized Double-Blind, Placebo-Controlled Study of LEE011 in Combination with Letrozole for the Treatment of Postmenopausal Women with Hormone Receptor Positive, HER2-Negative, Advanced Breast Cancer who Received No Prior Therapy for Advanced Disease
Principal Investigator: Anne Favret, MD
For more information on this clinical trial, call 703-208-3192
 Open
Galena Biopharma PH3-01 "PRESENT"

A Efficacy and Safety Study of NeuVax™ Vaccine to Prevent Breast Cancer Recurrence
Principal Investigator: Nicholas J. Robert, MD
For more information on this clinical trial, call 703-208-3192
 Open
USO 11-143
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of TKI258 Combined with Fulvestrant, in Postmenopausal Patients with HER2- and HR+ Breast Cancer that Have Evidence of Disease Progression on or after Prior Endocrine Therapy
Principal Investigator: Neelima Denduluri, MD
For more information on this clinical trial, call 703-208-3192
 Open


Chronic Lymphocytic Leukemia

Protocol/Organization Study Title/Purpose Status
USO-12-154
A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability and Pharmacodynamics of GS-9973 in Subjects with Relapsed or Refractory Hematologic Malignancies (GS-US-339-0102)
Principal Investigator: Dipti Patel-Donnelly, MD
For more information on this clinical trial, call 703-208-3192
 Open


Metastatic Colorectal Cancer

Protocol/Organization Study Title/Purpose Status
CALGB/SWOG C80702
A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer
Principal Investigator: Mary Wilkinson, MD
Contact Person: Maria Agra, RN, 703-720-5210 
 Open


Diffuse Large B-Cell Lymphoma

Protocol/Organization Study Title/Purpose Status
USO 13-060
A Phase I Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of JNJ-42756493, A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, in Subjects with Advanced or Refractory Solid Tumors or Lymphoma
Principal Investigator: Alex Spira, MD, PhD, FACP
For more information on this clinical trial, call 703-208-3192 
 Open
USO 13-152
A Multicenter Phase II Study with Safety Run-in Evaluating the Efficacy and Safety of Ublituximab in Combination with Ibrutinib in Patients with Select B-Cell Malignancies
Principal Investigator: Alex Spira, MD, PhD, FACP
For more information on this clinical trial, call 703-208-3192 
 Open
USOR 13-056
A Phase 2 Study of Brentuximab Vedotin in Combination with Standard of Care Treatment (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone [RCHOP]) as Front-Line Therapy in Patients with Diffuse Large B-Cell Lymphoma (DLBCL)
Principal Investigator: Dipti Patel-Donnelly, MD
For more information on this clinical trial, call 703-208-3192 
 Open
USO 12-154
A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability and Pharmacodynamics of GS-9973 in Subjects with Relapsed or Refractory Hematologic Malignancies (GS-US-339-0102)
Principal Investigator: Dipti Patel-Donnelly, MD
For more information on this clinical trial, call 703-208-3192 
 Open


Endometrium (Uterine)

Protocol/Organization Study Title/Purpose Status
Walter Reed
E39
Phase Ib Trial of  Folate Binding Protein (FBP) Peptide (E39) Vaccine in Ovarian and Endometrial Cancer Patients
Principal Investigator: John Elkas, MD
Contact Person: Kelly Jeffords, CCRC, CCRP, 571-308-1830, ext. 344
Open
Walter Reed Tissue and Data Acquisition for the Study of Gynecologic Disease
Principal Investigator: John Elkas, MD
Contact Person: Kelly Jeffords, CCRC, CCRP, 571-308-1830, ext. 344
Open
Caris Dx A Registry of Caris Life Science® Molecular Intelligence Service (Biomarker Assessment Results) Intended for Correlation with Cancer Clinical Outcomes
Principal Investigator: Larry Maxwell, MD
Contact Person: Kelly Jeffords, CCRC, CCRP, 571-308-1830, ext. 344
Open
Aetrna Zentaris Endometrial CA Randomized Controlled Study Comparing AEZS-108 with Doxorubicin as a Second Line Therapy for Locally Advanced Endometrial Cancer
Principal Investigator: Larry Maxwell, MD
Contact Person: Kelly Jeffords, CCRC, CCRP, 571-308-1830, ext. 344
Open


Gastric/Gastroesophageal Junction

Protocol/Organization Study Title/Purpose Status
USOR 13-053 A Phase Ib/II Clinical Study of BBI608 Administered with Paclitaxel in Adult Patients with Advanced Malignancies
Principal Investigator: Alex Spira, MD, PhD, FACP
For more information on this clinical trial, call 703-208-3192 
Open
USO 12-124 A Double-Blind, Placebo-Controlled, Randomized, Multicenter Phase III Study Evaluating the Efficacy and Safety of Pertuzamab in Combination with Trastuzumab and Chemotherapy in Patients with HER2-Positive Metastatic Gastroesophageal Junction and Gastric Cancer
For more information on this clinical trial, call 703-208-3192 
Open


Head and Neck

Protocol/Organization Study Title/Purpose Status
VentriRx Pharmaceuticals VRXP-A202 A Randomized, Double-Blind, Placebo-Controlled Study of Chemotherapy Plus Cetuximab in Combination with VTX 2337 in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Principal Investigator: Alex Spira, MD, PhD, FACP
For more information on this clinical trial, call 703-208-3192 
Open


Hodgkin's Lymphoma

Protocol/Organization Study Title/Purpose Status
USO 12-176 A Randomized, Open-Label, Phase 3 Trial of A+AVD versus ABVD as Frontline Therapy in Patients with Advanced Classical Hodgkin's Lymphoma
For more information on this clinical trial, call 703-208-3192 
Open
USO 11-282 A Phase 2 Open-Label Study of Brentuximab Vedotin in Front-Line Therapy of Hodgkin's Lymphoma (HL) in Adults Age 60 and Above
For more information on this clinical trial, call 703-208-3192 
Open


Interventional Radiology

Protocol/Organization Study Title/Purpose Status
  A Humanitarian Device Exemption Treatment Protocol of TheraSphere® for Treatment of Unresectable Hepatocellular Carcinoma and Tumors Metastatic to the Liver
Principal Investigator: Calvin Neithamer, MD, FACR
Contact Person: Christina Krawiecki, 703-776-4021
 Open


Mantle Cell Lymphoma

Protocol/Organization Study Title/Purpose Status
USO 13-060 A Phase I Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of JNY-42756493, A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, in Subjects with Advanced or Refractory Solid Tumors or Lymphoma
Principal Investigator: Alex Spira, MD, PhD, FACP
For more information on this clinical trial, call 703-208-3192 
 Open
USO 12-154 A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability and Pharmacodynamics of GS-9973 in Subjects with Relapsed or Refractory Hematologic Malignancies (GS-US-339-0102)
Principal Investigator: Dipti Patel-Donnelly, MD
For more information on this clinical trial, call 703-208-3192 
 Open


Melanoma

Protocol/Organization Study Title/Purpose Status
USOR 13-079 A Phase III Randomized, 3-Arm, Open Label, Multicenter Study of LGX818 Plus MEK162 and LGX818 Monotherapy Compared with Vemurafenib in Patients with Unresectable or Metastatic BRAF V600 Mutant Melanoma
Principal Investigator: Alex Spira, MD, PhD, FACP
For more information on this clinical trial, call 703-208-3192
Open


Multiple Myeloma

Protocol/Organization Study Title/Purpose Status
Multiple Myeloma Research Foundation MMRF-11-001 "CoMMpass" A Prospective, Longitudinal, Observational Study in Newly Diagnosed Multiple Myeloma (MM) Patients to Assess the Relationship Between Patient Outcomes, Treatment Options and Molecular Profiles
Principal Investigator: Gregory J. Orloff, MD
For more information on this clinical trial, call 703-208-3192
Open
Emory University MMRC-037 A Phase I Study of Ganetespib +/- Bortezomib in Patients with Relapsed and/or Refractory Multiple Myeloma
Principal Investigator: Gregory J. Orloff, MD
For more information on this clinical trial, call 703-208-3192
Open
Array BioPharma ARRAY-520-216 A Multicenter, Randomized, Open-Label, Non-Comparative Phase 2 Study of Carfilzomib with or without ARRAY-520 in Patients with Advanced Multiple Myeloma
Principal Investigator: Gregory J. Orloff, MD
For more information on this clinical trial, call 703-208-3192
Open
USO-09-141 CONNECT™ MM – The Multiple Myeloma Disase Registry – Registry Protocol
Principal Investigator: Dipti Patel-Donnelly, MD
For more information on this clinical trial, call 703-208-3192
Open


Non-Hodgkin's Lymphoma

Protocol/Organization Study Title/Purpose Status
USO-13-060 A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of JNJ-42756493, A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, in Subjects with Advanced or Refractory Solid Tumors or Lymphoma
Principal Investigator: Alex Spira, MD, PhD, FACP
For more information on this clinical trial, call 703-208-3192
Open
USO-12-154 A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability and Pharmacodynamics of GS-9973 in Subjects with Relapsed or Refractory Hematologic Malignancies (GS-US-339-0102)
Principal Investigator: Dipti Patel-Donnelly, MD
For more information on this clinical trial, call 703-208-3192
Open
USOR 11-262 SGN35-012: A Phase 2 Study of Brentuximab Vedotin in Relapsed or Refractory CD30-Positive Non-Hodgkin's Lymphoma (NHL)
Principal Investigator: Dipti Patel-Donnelly, MD
For more information on this clinical trial, call 703-208-3192
Open


Non-Small Cell Lung Cancer

Protocol/Organization Study Title/Purpose Status
Clovis CO-1680-008 TIGER X A Phase 2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)
Principal Investigator: Alex Spira, MD, PhD, FACP
For more information on this clinical trial, call 703-208-3192
Open
Roche NP28761 "ACCALIA2" A Phase I/II Study of the ALK Inhibitor CH5424802/RO5424802 in Patients with ALK-Rearranged Non-Small Cell Lung Cancer Previously Treated with Crizotinib
Principal Investigator: Alex Spira, MD, PhD, FACP
For more information on this clinical trial, call 703-208-3192
Open
Clovis CO-1686-019 "TIGER2" A Phase 2, Open-Label, Multicenter, Safety and Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC) Harboring the T790M Resistance Mutation
Principal Investigator: Alex Spira, MD, PhD, FACP
For more information on this clinical trial, call 703-208-3192
Open
Incyte INCB 18424-266 A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination with Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects with Nonsquamous Non-Small Cell Lung Cancer That Is Stage IIIB with Pleural/Pericardial Effusion, Stage IV or Recurrent
For more information on this clinical trial, call 703-208-3192 
Open
Daiichi Sankyo U31287-A-U301 A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter, Two-Part Study of Patritumab (U3-1287) in Combination with Erlotinib in EGFR Wild-Type Subjects with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Systemic Therapy
For more information on this clinical trial, call 703-208-3192
Open
Astellas 8273-CL-0102 An Open-Label, Phase 1 Dose Escalation Study of Oral ASP8273 in Subjects with Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations
Principal Investigator: Alex Spira, MD, PhD, FACP
For more information on this clinical trial, call 703-208-3192
Open
USOR 12-218 An Open-Label, Non-Randomized, Multicenter Phase I/II Trial of RO5424802 Given Orally To Non-Small Cell Lung Cancer Patients Who Have ALK Mutation and Failed Crizotinib Treatment
Principal Investigator: Alex Spira, MD, PhD, FACP
For more information on this clinical trial, call 703-208-3192
Open
USO 13-135 A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of MPDL3280A (Anti-PD-L1 Antibody) Compared with Docetaxel in Patients with Non-Small Cell Lung Cancer after Failure with Platinum-Containing Chemotherapy
Principal Investigator: Alex Spira, MD, PhD, FACP
For more information on this clinical trial, call 703-208-3192
Open
Astex AT13387-05 A Study of HSP90 Inhibitor AT13387 Alone and in Combination with Crizotinib in The Treatment of Non-Small Cell Lung Cancer (NSCLC)
Principal Investigator: Alex Spira, MD, PhD, FACP
For more information on this clinical trial, call 703-208-3192
Open
Novartis LDK378A2303 A Phase III, Multicenter, Randomized, Open-Label Study of Oral LDK378 Versus Standard Chemotherapy in Adult Patients with ALK-Rearranged (ALK-Positive) Advanced Non-Small Cell Lung Cancer Who Have Been Treated with Chemotherapy (Platinum Doublet) and Crizotinib
Principal Investigator: Alex Spira, MD, PhD, FACP
For more information on this clinical trial, call 703-208-3192
Open
Teva TV1011-LC-303 "ENSPIRIT" A Multinational, Randomized, Open-Label Phase III Study of Custirsen (TV-1011/OGX-011) in Combination with Docetaxel Versus Docetaxel As A Second-Line Treatment in Patients with Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer
Principal Investigator: Alex Spira, MD, PhD, FACP
For more information on this clinical trial, call 703-208-3192
Open


Ovarian Cancer (additional studies listed under Endometrium)

Protocol/Organization Study Title/Purpose Status
Walter Reed
E39
Phase lb Trial of Folate Binding Protein (FBP) Peptide (E39) Vaccine in Ovarian and Endometrial Cancer Patients
Principal Investigator: John Elkas, MD
Contact Person: Kelly Jeffords, CCRC, CCRP, 571-308-1830, ext. 344
Listed under Endometrium
Walter Reed
Tissue and Data Acquisition for the Study of Gynecologic Disease
Principal Investigator: John Elkas, MD
Contact Person: Kelly Jeffords, CCRC, CCRP, 571-308-1830, ext. 344
Listed under Endometrium


Pancreatics

Protocol/Organization Study Title/Purpose Status
USOR 12-237 A Phase 2, Randomized, Multicenter Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase) Combined with Nab-Paclitaxel Plus Gemcitabine Compared with Nab-Paclitaxel Plus Gemcitabine in Subjects with Stage IV Previously Untreated Pancreatic Cancer
Principal Investigator: Raymond Wadlow, MD
For more information on this clinical trial, call 703-208-3192 
Open


Prostate

Protocol/Organization Study Title/Purpose Status
RTOG 0534 A Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients with a Rising PSA after Radical Prostatectomy
Principal Investigator: Matt Poggi, MD
Contact Person: Chloe Hamilton, RN, BSN, OCN, 703-504-7900 or 703-504-7916
Open


Small Cell Lung Cancer

Protocol/Organization Study Title/Purpose Status
OncoMed 59R5-003 "PINNACLE" A Phase 1b/2 Study of OMP-59R5 in Combination with Etoposide and Cisplatin in Subjects with Untreated Extensive Stage Small Cell Lung Cancer
Principal Investigator: Alex Spira, MD, PhD, FACP
For more information on this clinical trial, call 703-208-3192
Open


Small Lymphocytic Leukemia

Protocol/Organization Study Title/Purpose Status
USO 12-154 A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability and Pharmacodynamics of GS-9973 in Subjects with Relapsed or Refractory Hematologic Malignancies (GS-US-339-0102)
Principal Investigator: Dipti Patel-Donnelly, MD
For more information on this clinical trial, call 703-208-3192
Open


Solid Tumors

Protocol/Organization Study Title/Purpose Status
USO 13-060 A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of JNJ-42756493, a Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, in Subjects with Advanced or Refractory Solid Tumors or Lymphoma
Principal Investigator: Alex Spira, MD, PhD, FACP
For more information on this clinical trial, call 703-208-3192
Open
13-090 STAR Modular Phase II Study to Link Targeted Therapy to Patients with Pathway Activated Tumors: Module 3-MEK162 for Patients with RAS/RAF/MEK Activated Tumors
For more information on this clinical trial, call 703-208-3192
Open
USO 13-020 Signature Series – Modular Phase II Study to Link Targeted Therapy to Patients with Pathway Activated Tumors: Module 1 – BKM120 for Patients with PI3K-Activated Tumors
For more information on this clinical trial, call 703-208-3192
Open
USO 13-070 Signature Series – Modular Phase II Study to Link Targeted Therapy to Patients with Pathway Activated Tumors: Module 2 – Dovitnib for Patients with Tumor Pathway Activations Inhibited by Dovitinib Including Tumors with Mutations or Translocations of FGFR, PDGFR, VEGF, cKIT, FLT3, CSFR1, Trk and RET
For more information on this clinical trial, call 703-208-3192
Open


Squamous (also listed under Head and Neck)

Protocol/Organization Study Title/Purpose Status
VentiRx Pharmaceuticals VRXP-A202 A Randomized, Double-Blind Placebo-Controlled Study of Chemotherapy Plus Cetuximab in Combination with VTX 2337 in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Principal Investigator: Alex Spira, MD, PhD, FACP
For more information on this clinical trial, call 703-208-3192
Open